Cansino Biologics Ownership

688185 Stock   61.23  0.13  0.21%   
Cansino Biologics holds a total of 114.78 Million outstanding shares. Cansino Biologics shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 62.9 percent of Cansino Biologics outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Cansino Biologics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Cansino Biologics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
As of December 24, 2024, Dividends Paid is expected to decline to about 60.8 M. As of December 24, 2024, Common Stock Shares Outstanding is expected to decline to about 259.1 M. The current year's Net Loss is expected to grow to about (993.6 M).
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cansino Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Cansino Stock Ownership Analysis

About 63.0% of the company shares are owned by insiders or employees . The book value of Cansino Biologics was presently reported as 20.58. The company recorded a loss per share of 3.51. Cansino Biologics last dividend was issued on the 23rd of August 2022. For more info on Cansino Biologics please contact the company at 86 022 5821 3600 or go to https://www.cansinotech.com.

Cansino Biologics Outstanding Bonds

Cansino Biologics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cansino Biologics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cansino bonds can be classified according to their maturity, which is the date when Cansino Biologics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Currently Active Assets on Macroaxis

Other Information on Investing in Cansino Stock

Cansino Biologics financial ratios help investors to determine whether Cansino Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cansino with respect to the benefits of owning Cansino Biologics security.